Ge Healthcare Technologies Inc Stock Price, News & Analysis

Sutter Health and GE HealthCare (GEHC) have announced a seven-year strategic Care Alliance partnership, representing one of GE HealthCare's largest enterprise collaborations. The partnership aims to enhance imaging services across Sutter's 300+ facilities serving 3.5 million patients in California.

The alliance focuses on implementing advanced AI-powered imaging technology including PET/CT, SPECT/CT, MRI, CT, X-ray, nuclear medicine, and ultrasound systems. Key technologies include GE HealthCare's Omni Legend PET/CT, StarGuide SPECT/CT, and Vscan Air™ SL ultrasound with Caption AI™ software.

The collaboration will support Sutter's expansion plans, including new care sites across Northern California and specialized centers for heart, vascular, cancer, and neuroscience care. The partnership includes workforce development programs through Sutter Health University, focusing on training technologists, nurses, and physicians while promoting diversity in healthcare staffing.

GE HealthCare (GEHC) has scheduled the announcement of its fourth quarter and full year 2024 financial results for Thursday, February 13, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 a.m. Eastern Time (7:30 a.m. Central Time) on the same day. Investors can access the live webcast through the company's investor relations website, where the earnings release, financial information, and webcast replay will also be made available.

GE HealthCare (GEHC) has unveiled three new deep learning image processing solutions at RSNA 2024: Sonic DL for 3D, Clarify DL, and TrueFidelity DL. These innovations aim to enhance image quality and reduce scan times in medical imaging.

Key highlights include Sonic DL for 3D, which can reduce MRI scan times by up to 86%, Clarify DL for enhanced bone SPECT image quality with 98% better image resolution in clinical evaluations, and TrueFidelity DL for improved cardiac CT imaging.

These solutions join GE HealthCare's existing Effortless Recon DL portfolio, addressing the growing need for improved diagnostic imaging, particularly important as the U.S. expects over two million new cancer cases in 2024.

GE HealthCare (GEHC) showcases its commitment to sustainability at RSNA 2024, highlighting progress in reducing environmental impact while advancing patient care. The company achieved a 13% reduction in greenhouse gas emissions in 2023 and recovered 7,375 imaging machines, resulting in over 15 million pounds of reused material.

Key sustainable innovations include the CT motion syringeless injector, which reduced plastic waste by 84.6% at UW-Madison, and energy-efficient systems like Revolution Apex with Energy Saving Mode 2.0, cutting power consumption by up to 80%. The company also introduced a manganese-based MRI contrast agent as an alternative to gadolinium, addressing environmental concerns.

GE HealthCare (GEHC) has submitted a 510(k) application to the FDA for CleaRecon DL, an AI-based technology designed to enhance cone-beam computed tomography (CBCT) image quality in interventional procedures. The technology aims to remove image streaks and improve image interpretation confidence. To be available on Allia™ Image-Guided Solutions Systems, it represents GE HealthCare's commitment to advancing CBCT adoption. Additionally, the company is introducing OnWatch Predict, a predictive monitoring system for interventional image-guided systems designed to forecast component failures and reduce unplanned downtime.

GE HealthCare (GEHC) has agreed to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, aiming to assume full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures. The company operates 13 manufacturing facilities and focuses on research and development of radiotracers and theranostics. The transaction, expected to close in early 2025 subject to regulatory approvals, will strengthen GE HealthCare's Pharmaceutical Diagnostics segment and enhance patient access to next-generation radiopharmaceuticals in Japan and Asian markets.

GE HealthCare has unveiled Sonic DL for 3D, expanding its MRI deep learning capabilities. The technology enables up to 86% faster scans and enhanced resolution for brain, spine, orthopedic, and body imaging. Building on the success of AIR Recon DL, which has helped over 34 million patients, Sonic DL provides up to 12x scan acceleration while maintaining diagnostic quality. When combined with AIR Recon DL's noise reduction technology, it can enhance image resolution by up to 55%. The solution aims to address healthcare burnout issues while improving workflow efficiency and patient comfort through faster, high-quality imaging for the majority of MR exams.

GE HealthCare will showcase over 40 innovations at RSNA 2024, including AI-enabled technologies focused on optimizing patient care and operational efficiency. The company is introducing several key solutions including Clarify DL for bone image reconstruction, nCommand Lite for remote collaboration, and enhanced True PACS with AI integration. Notable launches include CareIntellect for Oncology, a cloud-first application using generative AI for patient data management, and new theranostics solutions including MINItrace Magni cyclotron and Omni Legend with 21 cm configuration. These innovations reflect GE HealthCare's increased R&D investment since 2022 and address growing challenges in radiology.

GE HealthCare has unveiled the new Pristina Via mammography system at RSNA 2024, designed to enhance breast screening efficiency amid growing technologist shortages. The system features zero-click acquisition, faster image-to-image cycle time, and vendor-neutral prior image comparison.

Developed through extensive collaboration with technologists, including 250 interviews and observations, the system addresses the challenge of increasing vacancy rates (18% in 2024) while maintaining steady mammogram demand. Pristina Via offers the lowest radiation dose among major mammography systems and demonstrates 99% uptime under service contracts.